Boule Diagnostics (BOUL) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales were SEK 137 million, down 2.5% year-over-year, with organic growth at -3.6% and currency impact +1.1%.

• Adjusted EBIT improved 13.8% to SEK 9.9 million, with adjusted operating margin rising to 7.2% from 6.2%.

• Organizational restructuring reduced headcount by eight, targeting annual gross savings of SEK 8 million and incurring SEK 8.5 million in one-time costs.

• Cash flow from operating activities increased to SEK 13.8 million, up from SEK 3.4 million last year; liquidity at SEK 82 million including unused credit.

• Strategic priorities include margin expansion, organic growth acceleration, and portfolio enhancement, with continued investment in R&D and technology.

Financial highlights

• Adjusted gross profit was SEK 59.8 million, with gross margin at 43.6% (up from 42.7%).

• Adjusted EBIT was SEK 9.9 million, margin 7.2% (6.2%); net income was -1.6 million SEK.

• Adjusted operating expenses decreased to SEK 49.6 million from SEK 52.2 million.

• Earnings per share was -0.04 SEK, down from 0.11 SEK.

• Available liquidity at quarter-end was SEK 82 million.

Outlook and guidance

• Focus remains on margin expansion, cost optimization, and disciplined execution.

• Strategic investments in technology, OEM consumables, and veterinary channel expansion to drive future growth.

• India license manufacturing for M20 device on track for Q4 2024; BM950 performance evaluation set for H2 2024.

• No specific forward-looking statements or forecasts for H2 2024.

• Long-term targets: operating margin >15%, sales growth >10%, net debt/EBIT <3x.